Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
Thiazides to prevent rolling stones - the Ten Tweet summary of NOSTONE is here.
Welcome to #TenTweetNephJC - we’re again covering a practice changing trial, but unfortunately one that shows a treatment we’ve prescribed for decades for kidney stone prevention ain’t doing a huge amount....🧵 pic.twitter.com/j23gn9grw1
— Nephrology Journal Club (@NephJC) May 3, 2023
Check out the crisp VA on NOSTONE trial by Renz Pasilan
